How to read a cannabis oil lab report for potency and purity

A cannabis oil lab report, often called a certificate of analysis (COA), is the best available record of what was tested in a particular product batch. It can show the measured amounts of cannabinoids, identify unwanted substances and confirm whether the sample met the laboratory’s specifications. For Australian patients considering medicinal cannabis, learning to read this document helps separate reliable product information from vague marketing claims.

A COA does not prove that an oil is suitable for every person or condition. It is a quality document, not a diagnosis, prescription or treatment guarantee. The report should be read alongside advice from an Australian-registered doctor or pharmacist, especially when cannabis medicine is being considered for cancer-related symptoms, persistent pain, sleep problems or use with other medicines.

Start with the batch details and laboratory identity

The first section to check is the product identity. The report should name the product, formulation, batch or lot number, sample type and date of manufacture or testing. Those details must match the bottle, outer packaging or dispensing label. A report for a different batch does not reliably describe the oil in your hand, even when the product name is identical.

Look for a report date that makes sense in relation to the product’s shelf life. Some laboratories list the date they received the sample, while others show the date testing was completed. A credible document should also identify the laboratory, its address and the testing method. Australian consumers may see reports from laboratories in Australia, Europe, North America or other jurisdictions, particularly when products are imported through regulated pathways. The location matters less than traceable methods, consistent records and appropriate accreditation.

Accreditation can provide useful reassurance. Terms such as ISO/IEC 17025 indicate that a laboratory has been assessed for technical competence in testing and calibration. Accreditation does not make a product automatically safe, and its scope may cover some tests but not others. If the report lists an accreditation number, it can be checked through the relevant accreditation body rather than accepted as a decorative logo.

A genuine COA should be easy to connect to the product’s packaging. Be cautious if the document has no batch number, uses an old sample date, contains spelling or calculation errors, or appears to apply to an entire product range. A QR code can be convenient, although it should open a record that includes the same identifying information rather than a generic product page.

Read cannabinoid potency in the right units

The potency section usually lists tetrahydrocannabinol (THC), cannabidiol (CBD) and smaller cannabinoids such as cannabigerol (CBG), cannabinol (CBN), tetrahydrocannabivarin (THCV) or acidic forms such as THCA and CBDA. It may report results as a percentage by weight, milligrams per gram, milligrams per millilitre or total milligrams per container. These units are not interchangeable without knowing the product density and package volume.

For an oil, milligrams per millilitre are often the most practical figure. If the COA reports 20 mg of CBD per mL and the bottle contains 10 mL, the total labelled CBD would be approximately 200 mg. If a dropper delivers 0.5 mL, that portion would contain approximately 10 mg of CBD, assuming the oil is evenly mixed. The actual amount taken should follow the prescriber’s directions, since dropper sizes and fill markings vary.

THC deserves particular attention. A product described as “full spectrum” may contain measurable THC, even when CBD is the dominant cannabinoid. A “broad spectrum” product generally has THC removed or reduced, but the report should confirm the result rather than relying on the label. “THC-free” can be used in different ways, so check whether the result means no THC was detected or simply that it was below the laboratory’s reporting limit.

Look for the laboratory’s limit of detection or limit of quantification. “ND” usually means not detected, not that the substance is absolutely absent. A result below the reporting threshold may still be a very small amount. This distinction is important for people who must avoid THC because of side effects, workplace testing, driving obligations or legal requirements.

A potency result can also be expressed with a permitted range. For example, a label may state a target concentration while the report records a measured result slightly above or below it. Small variation is common in botanical products, but large discrepancies deserve an explanation from the supplier or pharmacist. Compare the report’s units with the label rather than judging quality from a large number alone.

Check the purity and contamination panels

The purity section should address substances that may enter cannabis oil during cultivation, extraction, manufacturing or storage. Common panels include pesticides, heavy metals, microbial contamination, residual solvents and mycotoxins. Depending on the formulation, testing may also cover foreign matter, moisture, water activity and stability.

For pesticide testing, the report may list many individual compounds with results such as “pass”, “ND” or a numerical concentration. A simple pass statement is less informative than a document showing which compounds were tested and the reporting limit. Heavy-metal results commonly include lead, arsenic, mercury and cadmium. These substances can accumulate in plant material, so a clean result matters particularly for people with complex medical conditions or long-term exposure.

Residual-solvent testing is relevant when ethanol, hydrocarbons or other solvents have been used during extraction. The report should name the solvents assessed and show whether each result met the applicable limit. An oil made through a solvent-free process may still require other contamination testing; “solvent-free” does not mean free of pesticides, metals or microorganisms.

Microbial results need to be interpreted according to the form of the product. Oils with very low water content may present a different microbial risk from water-based preparations, oral liquids containing added ingredients or products handled after manufacture. A report that says “microbial pass” without identifying the organisms or test criteria gives limited information.

Purity also includes the ingredients listed on the label. Check the carrier oil, flavourings, preservatives and allergens against the COA or product specification. MCT oil, olive oil and other carriers can affect tolerability and absorption. A person with food allergies, swallowing difficulties or a sensitive stomach may need advice about the complete formulation rather than the cannabinoid concentration alone.

Understand methods, uncertainty and red flags

A laboratory result is meaningful only in the context of its method. High-performance liquid chromatography, commonly abbreviated as HPLC, is frequently used for cannabinoid potency because it can measure acidic and neutral cannabinoids without the same heat exposure used in some other techniques. Gas chromatography may be used for selected compounds, although heat can alter acidic cannabinoids. The report should identify the technique or refer to a method number.

Some reports display a chromatogram, which is a graph showing peaks for detected compounds. The names and positions of those peaks should correspond to reference standards. A graph by itself is not proof of accurate dosing, but it can support a traceable analytical record when paired with sample information and numerical results.

Pay attention to measurement uncertainty, especially when results are close to a limit. A reported concentration is an estimate based on a sample, equipment and analytical procedure. Sampling can be important because a thick oil may not be perfectly uniform if it has been stored poorly or has not been mixed during production. A trustworthy manufacturer should have controls for homogeneity, filling and storage.

Red flags include a report with no test date, no sample identifier, no laboratory name, no units or no contamination results. Be cautious when every batch has exactly the same numbers, when the document uses only promotional language, or when a supplier refuses to provide a batch-specific report. A third-party report is useful, but the laboratory’s independence and the chain of custody still matter.

The word “organic” does not replace a pesticide panel, and “pharmaceutical grade” is not a complete quality assessment by itself. Similarly, “natural” says little about potency, contaminants or interactions. A product intended for oral use should not automatically be assumed safe for rectal administration or another route. Different routes can involve different excipients, absorption patterns and manufacturing requirements.

Apply the information to Australian treatment decisions

In Australia, medicinal cannabis is generally prescription-only. Access commonly involves an authorised prescriber and, where required, the Therapeutic Goods Administration’s Special Access Scheme or Authorised Prescriber pathway. State and territory rules can affect prescribing, supply and possession. A product purchased online from overseas is not automatically lawful to import or safe to use, and personal importation can involve customs and TGA requirements.

The local market has expanded through clinics, community pharmacies and telehealth services in cities such as Sydney, Melbourne, Brisbane, Perth and Adelaide. Availability can vary between pharmacies, and a product may be out of stock even when a prescription is valid. Patients in regional New South Wales, Queensland or Western Australia may face extra delivery time and fewer local dispensing options. Checking the actual batch report with the dispensing pharmacy is more useful than relying on a social media review.

Australian driving laws create a practical issue for THC-containing products. THC can remain detectable after the noticeable effects have worn off, and roadside testing rules differ by state and territory. CBD products may also contain trace THC. Anyone who drives to work, cares for children or operates machinery should discuss the product and timing with a prescriber and follow local law rather than assuming a low-THC label removes all risk.

Everyday habits can affect how an oil is used. Many Australians take medicines with breakfast, coffee or an evening meal, while shift workers may have irregular schedules. Taking an oil with food can alter absorption, and alcohol or sedating medicines may increase impairment or drowsiness. Keep a record of the batch number, dose, time, effects and adverse reactions, particularly when a formulation changes.

For people seeking a structured review of treatment information, CBD International’s patient resources describe products, consultations and ongoing support. Any information obtained there should still be checked against Australian prescribing rules and the advice of the clinician responsible for care. Patients can also use an application process as an administrative starting point, while confirming who will prescribe, where the product will be dispensed and how laboratory documentation is supplied.

A report cannot predict whether cannabis medicine will relieve pain, nausea or other symptoms. It can show whether the product’s stated identity, cannabinoid profile and quality testing are supported by evidence. Discuss interactions with chemotherapy, immunotherapy, anticoagulants, anti-seizure medicines, opioids and sleeping tablets, since CBD and THC can affect drug metabolism and the central nervous system. Do not replace cancer treatment or alter prescribed medicines on the basis of a COA.

Before using a cannabis oil, match the batch number to the label, confirm the CBD and THC amounts in practical units, review the contamination panel, check the laboratory method and record any reporting limits. Take the document to an Australian doctor or pharmacist when discussing dose, route, driving, interactions and legal supply. This simple process turns a laboratory report from a marketing attachment into a useful part of informed, safer medicine decisions.